Biological E's Corbevax gets DCGI nod as a Heterologous Covid Booster Dose

June 05, 2022
Current Context: The Hyderabad-based company has come up with a booster dose of Corbevax that increased the neutralizing antibody titers in the Covishield and Covaxin groups significantly when compared to placebo.
Biological E's Corbevax gets DCGI nod as a Heterologous Covid Booster Dose
  • Recently the Drug Controller General of India (DCGI) approved Biological E’s Corbevax and it becomes the first vaccine to get to be used as a heterologous booster for adults who have either received two shots of Covaxin or Covishield.
  • As of now, India was using a homologous booster shot for all precaution doses. Now, this become the first heterologous booster for adults.
  • Corbevax shot can be booked through the Co-WIN portal by anyone who wished to take a shot.
  • Corbevax booster dose provided significant enhancement in immune response and excellent safety profile required for an effective booster.
  • Apart from that, it has been claimed that there were no severe or adverse events of interest for 3 months of follow-up after the booster dose was administered.
  • Homologous boosters increased neutralizing antibody titers by a factor of 4 to 20, whereas heterologous boosters increased titers by a factor of 6 to 73.

Question:

Q.1 DGCA approved Corbevax Booster is a __________type of booster which is used for adults?
a. Homologous
b. Heterologous
c. Mixed
d. Double strain booster

Free Exam Resources

Useful material to support your preparation, revision and exam planning.

Continue on BankExamsToday

Revise notes, practice questions and resume anytime.

Meet your mentor

From the Founder

Ramandeep Singh, founder of BankExamsToday

Ramandeep Singh

Banking Educator · Former Banker

Former banker and educator helping aspirants prepare for banking promotion and specialist officer exams with focused, practical guidance.

14+
Years' experience
5,000+
Selections
Ex-BoB
Banking experience